FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.
Stocks · News reference
8-K filing — Travere Therapeutics, Inc. (TVTX)
Filed: 2026-09-21 AccNo: 0001438533-26-000068 Size: 505 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
Travere Therapeutics Says USPTO Allowed Patent For FILSPARI In FSGS, Expected To Provide Coverage Into October 2037
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.